Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster dose study of 10-valent pneumococcal conjugate vaccine versus Prevenar in toddlers previously vaccinated in infancy
2006-001628-38Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-blind trial of 10-valent pneumococcal conjugate vaccine, pneumococcal 7-valent conjugate vaccine and DTaP-IPV-HB-Hib vaccine in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoints: Post-immunization febrile reaction and Safety. Started Jun 2006; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccinepneumococcal 7-valent conjugate vaccineDTaP-IPV-HB-Hib vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2006-001628-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001628-38.